Status:
COMPLETED
A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics
Lead Sponsor:
Pfizer
Conditions:
Asthma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is an initial proof of concept, phase to study to assess the safety and efficacy tofimilast for the chronic maintenance treatment of adults with persistent asthma
Eligibility Criteria
Inclusion
- Mild to moderate persistent asthma (NAEPP/GINA Step 2-3)
- Reversibility to albuterol at least 12% and 200 mL
Exclusion
- Any significant co-morbid disease, particularly cardiovascular
- Use of any maintenance therapy except short acting bronchodilators
- Smoking history \> or = 10 years
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT00150397
Start Date
March 1 2005
End Date
November 1 2005
Last Update
June 8 2012
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Encinitas, California, United States, 92024
2
Pfizer Investigational Site
Riverside, California, United States, 92506
3
Pfizer Investigational Site
DeLand, Florida, United States, 32720
4
Pfizer Investigational Site
Atlanta, Georgia, United States, 30281